Groups | Day 0 | Day 7 | Day 14 | Day 28 | Day 42 |
---|---|---|---|---|---|
A | 15.90 ± 2.33 | — | — | — | — |
B | — | 84.70 ± 3.47 | 118.20 ± 3.65 | 60.40 ± 5.23 | 40.30 ± 5.74 |
C | — | 53.8 ± 5.07*† | 78.30 ± 4.22*† | 26.90 ± 4.18*† | 20.0 ± 3.83*† |
D | — | 64.10 ± 3.38* | 96.40 ± 6.59* | 38.50 ± 3.92* | 27.20 ± 4.44* |
↵* p<0.01 compared with group B (day 7, p=0.000, day 14, p=0.000, day 28, p=0.000, day 42, p=0.000),
↵† p<0.01 compared with group D (day 7, p=0.000, day 14, p=0.000, day 28, p=0.000, day 42, p=0.002). A - healthy controls, B - facial nerve lesion model + normal saline injection, C facial nerve lesion model + NGF injection through the stylomastoid foramen, D facial nerve lesion model + intraperitoneal injection of NGF